DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Ramoplanin
Ramoplanin
Investigational Drug Therapies Currently in Early-Stage Clinical Development for the Treatment of Clostridioides (Clostridium) Difficile Infection Mai-Chi N
Effect of Msa on Antibiotic Resistance and Allelic Replacement of Pkor1 in Staphylococcus Aureus
Chemical Probes to Visualize Bacterial Cell Structure and Physiology
Identifying Targets for Potentiators in S. Aureus Using Chemical Genetic Approaches
Antibiotics Currently in Clinical Development
Oral Presentations
Recent Advances in the Development of Antibacterial Agents
Advances in Antimicrobial Resistance Monitoring Using Sensors and Biosensors: a Review
Ramoplanin PRODUCT DATA SHEET Issue Date 01/06/2020
Resistance of Anaerobic Bacteria Can We Find Any Clinical Impact
Antibiotics Currently in Global Clinical Development Note: This Data Visualization Was Updated in September 2018 with New Data
GENOME THERAPEUTICS 2003 ANNUAL REPORT Introducing A
Liposidomycin, the First Reported Nucleoside Antibiotic Inhibitor of Peptidoglycan Biosynthesis Translocase I
Critically Important Antimicrobials for Human Medicine – 5Th Revision. Geneva
Mini-Review Antibiotic Prophylaxis in Patients Receiving Hematopoietic Stem Cell Transplant
6-Veterinary-Medicinal-Products-Criteria-Designation-Antimicrobials-Be-Reserved-Treatment
A Crystal Structure of a Dimer of the Antibiotic Ramoplanin Illustrates Membrane Positioning and a Potential Lipid II Docking Interface
Deacylation of Glycopeptide Antibiotic A40926 by Immobilized Actinoplanes Teichomyceticus Cells - in Quest of Better Drugs Against MRSA
Top View
Effectiveness of Early Diagnosis, Prevention, and Treatment of Clostridium Difficile Infection Comparative Effectiveness Review Number 31
Ambush of Clostridium Difficile Spores by Ramoplanin
Production of Ramoplanin and Ramoplanin Analogs by Actinomycetes
Ramoplanin at Bactericidal Concentrations Induces Bacterial Membrane Depolarization in Staphylococcus Aureus
Bad Bugs Need Drugs: an Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America
2019 Antibacterial Agents in Clinical Development
The Bacterial Challenge: Time to React
TML\MSH Microbiology Department Policy & Procedure Manual Policy
Bacterial Targets of Antibiotics in Methicillin-Resistant Staphylococcus Aureus
Antibiotics in the Clinical Pipeline in 2011
Categorisation of Antimicrobials” (EMA/CVMP/CHMP/682198/2017)
021883Orig1s000
Complexation of Peptidoglycan Intermediates by The
Critically Important Antimicrobials for Human Medicine, 6Th Revision
ANTIMICROBIAL AGENTS and CHEMOTHERAPY Volume 35 January 1991 No
Antibiotic Pipeline Surveillance – 2010 to Mid 2011 Cardinal Health Clinical Affairs (Phase I and Some Early Phase II Not Included)
Docking on Lipid II—A Widespread Mechanism for Potent Bactericidal Activities of Antibiotic Peptides
Clostridium Difficile: How Do We Stop the Flow?
Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated Or Fastidious Bacteria
Complexation of Peptidoglycan Intermediates by The
W O 2019/074870 a L 18 April 2019 (18.04.2019) W 1P O PCT
Ramoplanin at Bactericidal Concentrations Induces Bacterial Membrane Depolarization in Staphylococcus Aureus
The Enlarging Threat of Antibiotic Resistance
ANTIBACTERIAL AGENTS in CLINICAL DEVELOPMENT an Analysis of the Antibacterial Clinical Development Pipeline, Including Tuberculosis
Antibiotics in the Clinical Pipeline in 2013
2018 Update of Antibacterial Agents in Clinical Development Is Based on the Outcome of the Second Advisory Group Meeting That Was Held on 12 July 2018
The Bactericidal Activity and Spore Inhibition Effect of Manuka Honey
Functional Analysis of the Lipoglycodepsipeptide Antibiotic Ramoplanin
A Dual-Mechanism Antibiotic Targets Gram-Negative Bacteria and Avoids Drug Resistance 11 1 1,5 1 1 12 James K
Formation and Modification of Enduracididine, a Nonproteinogenic Amino Acid
Bacterial Cell Wall & Membrane